nicotinylalanine

structure given in first source

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Huntington Disease (Huntington's Disease) 05/01/1998 - "This study examined the potential of nicotinylalanine to influence excitotoxic damage to striatal NADPH diaphorase (NADPH-d) and gamma-aminobutyric acid (GABA)ergic neurones that are selectively lost in Huntington's disease. "
2.	Seizures (Absence Seizure) 03/01/1992 - "4. In mice the same dose of nicotinylalanine reduced the incidence of seizures induced by leptazol or electroshock treatment. "
3.	Multiple Sclerosis 08/06/2015 - "These observations led to the identification of potential therapeutic targets in multiple sclerosis, such as synthetic tryptophan analogs, endogenous tryptophan metabolites (e.g., cinnabarinic acid), structural analogs (laquinimod, teriflunomid, leflunomid and tranilast), indoleamine-2,3-dioxygenase inhibitors (1MT and berberine) and kynurenine-3-monooxygenase inhibitors (nicotinylalanine and Ro 61-8048). "

1.	NADPH Dehydrogenase (Dehydrogenase, NADP)
2.	NADP (NADPH)
3.	gamma-Aminobutyric Acid (GABA)
4.	Tryptophan (L-Tryptophan)
5.	Berberine
6.	laquinimod
7.	Ro 61-8048
8.	tranilast
9.	cinnabarinic acid